HHLR ADVISORS, LTD. - Q3 2019 holdings

$7.27 Billion is the total value of HHLR ADVISORS, LTD.'s 64 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 104.2% .

 Value Shares↓ Weighting
IQ BuyIQIYI INCsponsored ads$814,826,000
+171.9%
50,516,188
+248.1%
11.20%
+67.2%
BGNE BuyBEIGENE LTDsponsored adr$670,133,000
+21.8%
5,472,259
+23.3%
9.21%
-25.1%
TAL BuyTAL EDUCATION GROUPsponsored ads$487,151,000
+12.1%
14,227,551
+24.7%
6.70%
-31.1%
JD BuyJD COM INCspon adr cl a$454,739,000
-4.7%
16,119,769
+2.3%
6.25%
-41.4%
UBER NewUBER TECHNOLOGIES INC$375,589,00012,326,519
+100.0%
5.16%
SE BuySEA LTDsponsored ads$370,070,000
+159.1%
11,957,037
+178.1%
5.09%
+59.3%
BABA BuyALIBABA GROUP HLDG LTDsponsored ads$364,305,000
+52.3%
2,178,468
+54.3%
5.01%
-6.4%
PDD BuyPINDUODUO INCsponsored ads$359,144,000
+141.9%
11,146,615
+54.9%
4.94%
+48.7%
ESGR BuyENSTAR GROUP LIMITED$331,950,000
+250.5%
1,747,840
+221.6%
4.56%
+115.4%
EDU BuyNEW ORIENTAL ED & TECH GRP Ispon adr$305,840,000
+86.0%
2,761,282
+62.2%
4.20%
+14.3%
ALGN NewALIGN TECHNOLOGY INC$283,230,0001,565,500
+100.0%
3.89%
FB BuyFACEBOOK INCcl a$228,078,000
+0.2%
1,280,763
+8.6%
3.14%
-38.4%
BILI BuyBILIBILI INCspons ads rep z$181,200,000
+37.7%
12,832,876
+58.6%
2.49%
-15.4%
FGEN BuyFIBROGEN INC$129,552,000
+5.2%
3,503,287
+28.6%
1.78%
-35.3%
APLS BuyAPELLIS PHARMACEUTICALS INC$112,700,000
+72.4%
4,678,289
+81.3%
1.55%
+6.0%
GOSS BuyGOSSAMER BIO INC$99,255,000
+377.3%
5,911,541
+530.6%
1.36%
+193.3%
BBIO BuyBRIDGEBIO PHARMA INC$94,225,000
+48.5%
4,388,690
+86.5%
1.30%
-8.7%
AMZN NewAMAZON COM INC$84,115,00048,456
+100.0%
1.16%
NFLX NewNETFLIX INC$69,849,000261,002
+100.0%
0.96%
CVET NewCOVETRUS INC$47,063,0003,958,198
+100.0%
0.65%
MOMO BuyMOMO INCadr$42,907,000
+23.7%
1,385,000
+43.0%
0.59%
-23.9%
SDC NewSMILEDIRECTCLUB INC$40,572,0002,923,086
+100.0%
0.56%
NXTC BuyNEXTCURE INC$32,503,000
+2791.7%
1,053,570
+1304.8%
0.45%
+1688.0%
GMAB NewGENMAB A Ssponsored ads$30,390,0001,500,000
+100.0%
0.42%
AAPL NewAPPLE INC$28,614,000127,759
+100.0%
0.39%
SQ NewSQUARE INCcl a$26,556,000428,675
+100.0%
0.36%
MOGU BuyMOGU INCspon ads$26,273,000
+76.5%
10,446,970
+100.0%
0.36%
+8.4%
ZLAB NewZAI LAB LTDadr$25,815,000798,001
+100.0%
0.36%
UXIN NewUXIN LTDads$23,126,0009,439,181
+100.0%
0.32%
NIO NewNIO INCspon ads$20,855,00013,368,900
+100.0%
0.29%
HTHT NewHUAZHU GROUP LTDsponsored ads$20,191,000611,490
+100.0%
0.28%
ARVN BuyARVINAS INC$18,432,000
+34.1%
855,308
+36.8%
0.25%
-17.6%
MELI NewMERCADOLIBRE INC$17,970,00032,600
+100.0%
0.25%
AKRO BuyAKERO THERAPEUTICS INC$17,049,000
+109.5%
749,424
+76.3%
0.23%
+28.6%
RGNX BuyREGENXBIO INC$16,234,000
+53.4%
456,000
+121.4%
0.22%
-5.9%
KNSA BuyKINIKSA PHARMACEUTICALS LTD$15,893,000
-36.1%
1,867,622
+1.7%
0.22%
-60.8%
MRNA NewMODERNA INC$15,577,000978,434
+100.0%
0.21%
NOAH NewNOAH HLDGS LTDspon ads cl a$14,052,000481,220
+100.0%
0.19%
HOOK BuyHOOKIPA PHARMA INC$7,074,000
+267.9%
943,254
+230.1%
0.10%
+125.6%
RCUS BuyARCUS BIOSCIENCES INC$6,981,000
+106.6%
767,128
+80.5%
0.10%
+26.3%
IGMS NewIGM BIOSCIENCES INC$6,213,000350,000
+100.0%
0.08%
CJJD NewCHINA JO-JO DRUGSTORES INC$5,856,0004,840,000
+100.0%
0.08%
TCRR NewTCR2 THERAPEUTICS INC$4,853,000322,903
+100.0%
0.07%
TXG New10X GENOMICS INC$3,780,00075,000
+100.0%
0.05%
CBMG NewCELLULAR BIOMEDICINE GROUP I$3,495,000235,214
+100.0%
0.05%
CNST NewCONSTELLATION PHARMCETICLS I$1,595,000246,883
+100.0%
0.02%
SFUN NewFANG HLDGS LTDadr new$666,000300,000
+100.0%
0.01%
GSAHWS NewGS ACQUISITION HLDGS CORP*w exp 06/12/202$453,000333,333
+100.0%
0.01%
NTGN NewNEON THERAPEUTICS INC$103,00060,000
+100.0%
0.00%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BEIGENE LTD20Q3 202326.0%
JD.COM INC20Q3 202313.1%
IQIYI INC20Q3 202312.3%
MONDELEZ INTL INC20Q3 20235.9%
KINIKSA PHARMACEUTICALS LTD20Q3 20231.6%
SOHU COM LTD20Q3 20230.6%
PINDUODUO INC19Q3 202316.1%
GOSSAMER BIO INC19Q3 20232.3%
BRIDGEBIO PHARMA INC18Q3 20233.4%
MELCO RESORTS AND ENTMT LTD18Q1 20232.8%

View HHLR ADVISORS, LTD.'s complete holdings history.

Latest significant ownerships (13-D/G)
HHLR ADVISORS, LTD. Q3 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
I-MabJune 30, 202315,891,2118.3%
BeiGene, Ltd.February 14, 2023147,043,05810.9%
Gossamer Bio, Inc.February 14, 20234,974,0415.3%
On Holding AGFebruary 14, 20235,468,5041.9%
Root, Inc.February 14, 2023138,9771.5%
Yatsen Holding LtdFebruary 14, 2023300,560,60219.1%
iQIYI, Inc.July 11, 2022149,075,9125.0%
Apellis Pharmaceuticals, Inc.February 14, 2022? ?
Beam Therapeutics Inc.February 14, 2022? ?
Futu Holdings LtdFebruary 14, 20222-

View HHLR ADVISORS, LTD.'s complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
42024-02-01
13F-HR2023-11-14

View HHLR ADVISORS, LTD.'s complete filings history.

Compare quarters

Export HHLR ADVISORS, LTD.'s holdings